Please find enclosed intimation on allotment.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Vivo Bio Tech's board approved unaudited standalone and consolidated results for Q1 FY26 (quarter ended June 30, 2025) along with the allotment of 13,33,332 equity shares at Rs. 45 each (Rs. 10 face + Rs. 35 premium) on conversion of preferential warrants, bringing in about Rs. 4.5 crore. Standalone revenue from operations rose about 22.5% year-on-year to Rs. 1,241.86 lakhs, while profit after tax jumped from Rs. 17.79 lakhs to Rs. 137.32 lakhs. On a consolidated basis, revenue grew roughly 23.5% to Rs. 1,251.16 lakhs and PAT climbed from Rs. 16.64 lakhs to Rs. 133.71 lakhs. The auditor P. Murali & Co. issued an unqualified review report with no qualifications. Post-allotment, paid-up share capital increased to Rs. 21.33 crore divided into about 2.13 crore equity shares, indicating fresh dilution for existing shareholders.
Strong YoY growth in both revenue and profits points to improving business momentum, but PAT is bouncing off a low base and the EPS impact is modest (Rs. 0.76 standalone). The preferential warrant conversion has expanded the share count meaningfully, so investors should weigh dilution against the growth trajectory.